Clinical Research

The post thumbnail

Outsourcing Pharmaceutical R&D: Risks and Rewards

Outsourcing is a popular and profitable strategy that allows large companies to contract out what they consider to be non-critical processes and services – something most of us associate with routine customer service and IT support. Pharma companies have been key players in this trend for years, outsourcing almost everything in IT, including mainframes, networks and call centres. Over the past decade, progressive organizations have even begun contracting out human resources, finance and accounting, and facilities management. Since the late 1990s, GlaxoSmithKline, Novartis, Johnson & Johnson, and Pfizer have taken the lead in outsourcing an increasing number of operations.  It.. READ MORE »

The post thumbnail

Trends in Pharma Marketing: Re-Packaging Old Drugs

For many companies, marketing is no longer about mass distribution. It’s about tracking micro trends and reaching out to smaller, more niche demographics.  Nowadays, the marketing messages we receive are based on very specific criteria, like age, occupation, income level, and the last item we searched for on Google. So why does Big Pharma rely on out-dated techniques? Many industry giants still use the “door-to-door” approach where reps hand out starter samples to doctors, and television campaigns urge a wide spectrum of viewers to “ask their doctor” for new drug prescriptions. However, smaller pharmaceutical companies are finding ways to stay.. READ MORE »

The post thumbnail

High Tech Labs: Revolutionizing the Clinician’s Toolbox

From mapping genomes to new software for monitoring trials, new technologies are revolutionizing the every-day business of clinical research. The emphasis is on efficiency and accuracy: innovators are looking for ways to minimize errors in diagnostics and trial management, while maintaining patient health as the highest priority. This week we profile two technological advancements in clinical laboratory tools that achieve that delicate balance. The first tool upgrades diagnostics from manual to molecular, while the second provides project teams with a full-service trial management system that is rapidly closing the gap on error and oversight during clinical trials.   Molecular Diagnostics:.. READ MORE »

The post thumbnail

From Molecules to Manure: Uncovering a Cure for Allergies

Watery eyes, scratchy throat, angry rashes. From pesky annoyance to life threatening reaction: how many of us suffer from allergies? Health Canada says that non-food allergies have become chronic in people over the age of twelve. Over 65 million Americans have some sort of allergy, and in Europe over 87 million people struggle to control allergen sensitivities. Controlling allergies is a big business, and because typical treatments only ease symptoms rather than eliminating the root cause, allergies continue to torment their victims. On the quest for a definitive cure, researchers are on the lookout for new data and permanent solutions… READ MORE »

The post thumbnail

Mapping out the Future: Funding Boost for Canadian Genomics Initiatives

Since the first successful sequencing of the human genome in 2003, technology has evolved to make DNA mapping faster and more cost-effective than ever. In the health care sector, genomics has paved the way for customized therapies for patients suffering from a range of illnesses including cancer, HIV/AIDS, epilepsy, neurological conditions, and cardiovascular disease. A more complete understanding of a patient’s genetic map means more effectively targeted drugs and a more efficient health care system. Students currently enrolled in pharmaceutical courses will emerge into a marketplace where customizable drug therapies are a booming business. The power to examine the genomes.. READ MORE »

The post thumbnail

Designer Drugs: Risky Synthetics Flood the Canadian Market

Health Canada recently issued a warning regarding the dangers of psychoactive drugs, in particular synthetic blends that replicate the effects of controlled substances. The development and distribution of synthetics falls within a legal grey area, and has sparked new debate about how the government should regulate this new “market.” Without the safety measures associated with pharmaceutical quality control, synthetic psychoactive drugs like Acetyl Fentanyl are developed and sold with little knowledge regarding their safety or effects on users.  Psychoactive drugs impact brain functioning, and cause changes in mood and behavior; they are usually prescribed to treat physical and psychological disorders… READ MORE »

The post thumbnail

All About CETA and You

This month, after years of discussion, Canada signed a Canada-EU Free Trade deal. The Comprehensive Economic Trade Agreement (CETA) is testing the waters for dropping import tariffs on everything from cars to food in trade between Canada and the European Union’s member states.  Part of the agreement includes pharmaceutical imports, which is, understandably, a game changer for the industry. At this stage in negotiations, this includes establishing working groups to resolve differences in Canadian and European standards, not necessarily topics such as pharmaceutical quality assurance, which is already more or less in sync, but to help facilitate negotiations of the.. READ MORE »

The post thumbnail

Pharmaceutical Studies: A Frontrunner in Marketability

It was once believed that a university degree was all Canadians needed to secure relatively stable and desirable employment. But these days, students are graduating at the top of their class only to find themselves at the end of an unemployment line. A rocky economy and the changing landscape of post-secondary education have made choosing a program of study more confusing than ever.  In June of 2013, CBC News reported that unemployment rates for recent grads were at 14.5% and rising. Conditions are no better across the border, where the Wall Street Journal reported that last year 284,000 American college.. READ MORE »

The post thumbnail

Therapeutics Initiative Funding Attempts Gets International Attention

Last year in October, the province of BC defunded the Therapeutics Initiative program, an independent institution to monitor the effects of prescription pharmaceutical drugs. TI is also attached to the University of British Columbia’s Department of Family Practice, and had been working in this capacity since 1994. Defunding from the province did not kill the program. Instead, UBC picked up the shortfall, but TI garnered itself international attention as they campaigned for recognition, nationally and internationally, earning a mention in the prestigious British Medical Journal, as well as an open letter from doctors and research scientists from around the world,.. READ MORE »

The post thumbnail

Genetics-Based Pharmaceutical Research Breakthroughs

This week, we’re taking a look at some of the promising discoveries that have appeared over the last few months. They all share something in common: they all have roots in our ongoing efforts to understand the human genetic code and the biological processes surrounding it, part of a trend that’s opening up a whole range of new cures and treatments. Pharmaceutical discoveries and possible new treatments Messenger RNA (mRNA) normally serves an important role in copying DNA, as part of its transmission. Clinical research-oriented company, CureVac has partnered with pharmaceutical giant Janssen to build on existing, promising research. The.. READ MORE »

Archives